Pune: Here’s how Prime Minister Narendra Modi will spend his day in Pune on November 28

November 26, 2020
Pune: Prime Minister Narendra Modi is visiting Serum Institute of India (SII) in Hadapsar area of Pune city on Saturday (November 28). PM Modi will be spending one hour at the SII during which he will review the progress on COVID19 vaccine which is being produced by the global vaccine manufacturer.
Pune Divisional Commissioner Saurabh Rao shared the details of PM Modi’s visit to Pune city.
• PM Narendra Modi will arrive at the Pune Lohegaon Airport at 1230 hrs
• After arriving at airport, PM Modi will head to Serum Institute at Hadapsar
• PM Modi will be taking a chopper to reach Serum Institute
• PM Modi will be at the Serum Institute for a duration of one hour
• During his stay at the Serum Institute, Modi will review the status of Covid-19 vaccine
• After the visit, PM Modi will head back to Pune Lohegaon Airport
• PM Modi will leave for Hyderabad from Pune
• PM Narendra Modi will arrive at the Pune Lohegaon Airport at 1230 hrs
• After arriving at airport, PM Modi will head to Serum Institute at Hadapsar
• PM Modi will be taking a chopper to reach Serum Institute
• PM Modi will be at the Serum Institute for a duration of one hour
• During his stay at the Serum Institute, Modi will review the status of Covid-19 vaccine
• After the visit, PM Modi will head back to Pune Lohegaon Airport
• PM Modi will leave for Hyderabad from Pune
The district administration has started all preparations for this crucial visit of the Prime Minister. The Special Protection Group (SPG) for security of PM Modi has also arrived in the city and adequate security measures are being implemented. After PM Modi’s visit, about 100 Delhi-based foreign envoys will be visiting the Serum Institute on December 4.
The Serum Institute has partnered with Oxford University and AstraZeneca company to produce the Covid-19 vaccine. Oxford-AstraZeneca vaccine candidate is presently under Phase III human trials and has proven to be 70 per cent effective in the phase II trials. The enrollment of candidates for the phase III trials has been recently completed and now the results and conclusion of the phase III trials are awaited.
Comments are closed.